Company Media

Biotech Daily: Dr Boreham’s Crucible: Immuron

10 May 2024

Immuron is in the throes of multiple clinical trials to prove the efficacy of Travelan against specific diarrhoea-inducing pathogens.

The Watchlist: Immuron's Travelan sales growth, clinical pipeline achievements and upcoming milestones!

26 April 2024

CEO Steve Lydeamore provides an update on Travelan's exponential growth!

Immuron marks surge in Travelan® sales on eve of entry into US via

10 April 2024

Immuron Ltd (NASDAQ:IMRN, ASX:IMC), a biopharmaceutical company headquartered in Australia, says sales of its immune supplement Travelan® have soared.

Guarding Gut Health on the Go: The Travelan® Advantage

10 April 2024

The Not Old Better Show, Art of Living Interview Series. Today's episode takes us on a fascinating journey through the landscape of travel health, an essential yet often overlooked aspect of our adventures abroad.

Clinical data imminent!

6 February 2024

Immuron CEO Steve Lydeamore speaks about the clinical work it is doing with IMM-124e and IMM-529, its involvement with the Uniformed Services University and the Naval Medical Research Command, and the commercial opportunity for Travelan.

Beating bacteria just got boosted

11 November 2023

We might like experiencing new places, but our tummies don’t always agree with us. Here’s something that might suit some. Travelan is an immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal tract.

Immuron hails record monthly sales of Travelan

18 September 2023

Immuron Ltd (NASDAQ:IMRN, ASX:IMC) CEO Steve Lydeamore speaks with Proactive following news the company has achieved record monthly sales of its over-the-counter gastrointestinal supplement Travelan®

Immuron Ltd Newsletter (September 2023)

1 September 2023

Immuron Ltd newsletter September 2023. Updates on milesone achievements, sales, FY24 milestones and general Immuron Ltd news.

Q&A with Steven Lydeamore, CEO of Immuron Limited

23 August 2023

Immuron Limited is commercializing and developing a novel class of specifically targeted polyclonal antibodies which are delivered within the gastrointestinal tract and do not cross into the bloodstream.

Sequire Spotlight Presents Immuron Limited (IMRN): Creating New Products for Infectious Diseases

24 July 2023

Host Jonathan Miller interviews CEO: Steven Lydeamore. He talks about the exponential growth on sales in the past year.

Immuron on How their Gastrointestinal and Digestive Health Immune Supplements Work + FY23 Sales

20 July 2023

Planet MicroCap spoke with Steven Lydeamore, CEO of Immuron Ltd. (ASX: IMC) (NASDAQ: IMRN) via Zoom to discuss

Immuron Sees Substantial Sales Growth in FY23 Driven by Resurgence in Travel (ASX:IMC)

18 July 2023

Immuron Limited (ASX: IMC; NASDAQ: IMRN), the Melbourne-based biopharmaceutical firm, has reported a stellar performance for FY23 with a 136% surge in global sales compared to FY22.

Immuron to go ahead with IMM-529 cGMP manufacturing and proceed with FDA pre-IND submission

27 June 2023

The Board of Directors of Immuron Ltd (NASDAQ:IMRN, ASX:IMC) has given the green light for the company to proceed with IMM-529 cGMP manufacturing for the treatment of a form of gastrointestinal disease.

Immuron Limited Announces Participation in the LD Micro Invitational XIII

6 June 2023

Immuron Limited (ASX: IMC) (NASDAQ: IMRN) announced today that it will be presenting at the 13th Annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel, California on June 6th-8th, 2023

Innovation begins with collaboration: Steven Lydeamore

5 April 2023

Immuron Ltd (NASDAQ:IMRN, ASX:IMC) CEO Steven Lydeamore is a numbers guy. You can tell by the thoughtful, considered way he reflects on his experience that a knack for numbers has informed his leadership style.

Immuron grows revenue by 153% in H1 FY23 with more growth catalysts lined up

1 March 2023

Immuron Ltd posted a revenue of $584,000 in H1 FY23, a growth of 153% compared to H1 FY22, with Australian sales contributing $287,000.

Immuron Limited CEO Steven Lydeamore interview with Stuart Roberts Management Interview Series – Stocks Down Under

28 February 2023

Immuron Limited CEO Steven Lydeamore interview with Stuart Roberts Management Interview Series – Stocks Down Under

US recruitment milestone for trial of Immuron's Travelan

19 January 2023

Immuron (ASX:IMC) has updated on the US Department of Defense Uniformed Services University (USU) clinical evaluation of the company's Travelan.

Immuron working towards US FDA approval of Traveler’s Diarrhea product Travelan

18 January 2023

Immuron Limited CEO Steven Lydeamore joined Steve Darling from Proactive to share news about the Australian Biotech company that is looking at using its technology for product development around gut health

CEO Steven Lydeamore presents at The Capital Network's Emerging ASX Gems investment conference

4 November 2022

Immuron (ASX:IMC) CEO Steven Lydeamore presents at The Capital Network's Emerging ASX Gems investment conference on Friday 4 November 2022.